Long-lasting antibodies to treat eye diseases that cause vision loss
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases
This study is working on new long-lasting treatments for eye diseases that can cause vision loss, aiming to make it easier for patients by reducing the number of injections they need, so they can enjoy better eyesight and a more convenient treatment experience.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abzyme Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Pottstown, United States) |
| Project ID | NIH-11045761 on NIH RePORTER |
What this research studies
This research focuses on developing innovative long-acting antibodies to treat retinal neovascular diseases, which are serious conditions that can lead to vision loss. The approach involves creating antibodies that target specific factors involved in the disease process, such as VEGF and CD147, to reduce the need for frequent injections. By using advanced techniques, the researchers aim to improve the effectiveness and safety of treatments for conditions like age-related macular degeneration and diabetic macular edema. Patients may benefit from a more convenient treatment regimen that could enhance their quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from retinal neovascular diseases such as age-related macular degeneration or diabetic macular edema.
Not a fit: Patients with retinal diseases not related to neovascularization may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and less burdensome treatment option for retinal diseases.
How similar studies have performed: Previous research has shown promise in developing long-acting therapies for retinal diseases, indicating potential for success with this novel approach.
Where this research is happening
Pottstown, United States
- Abzyme Therapeutics, LLC — Pottstown, United States (Active)
Researchers
- Principal investigator: Tran, Hiep T — Abzyme Therapeutics, LLC
- Study coordinator: Tran, Hiep T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.